Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects

  • STATUS
    Recruiting
  • days left to enroll
    27
  • participants needed
    172
  • sponsor
    Grifols Therapeutics LLC
Updated on 28 January 2021

Summary

This is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during surgery in pediatric subjects.

Pediatric subjects (<18 years of age) requiring an elective (non-emergent), open (non-laparoscopic), pelvic, abdominal, or thoracic (non-cardiac) surgical procedure, wherein a target bleeding site (TBS) is identified, and a topical hemostatic agent is indicated, will be eligible to participate in the clinical trial.

The study treatments will be applied on the cut parenchymous surface of a solid organ (ie, liver) and in soft tissue (ie, fat, muscle, or connective tissue).

Description

This is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of FS Grifols as an adjunct to hemostasis during surgery. Approximately 172 pediatric subjects will be enrolled and will be randomly allocated in a 1:1 ratio into 1 of 2 treatment groups: FS Grifols or EVICEL. Enrollment will be monitored by surgery type to ensure at least 50% of the surgical procedures are hepatic.

A specific bleeding site will be defined as the TBS when it is determined by the investigator (the surgeon) that control of bleeding by conventional surgical techniques (including suture, ligature, and cautery) is ineffective or impractical and requires an adjunct treatment to achieve hemostasis.

When the TBS is identified, the investigator will record the precise anatomical location of the TBS, rate the intensity of the bleeding at the TBS (Grade 1-4 according to a 5-point validated bleeding severity scale), and record the size of the approximate bleeding surface, (small, medium, and large). For soft tissue surgery only, the investigator will also record the type of soft tissue (ie, fat, muscle, or connective tissue). In this clinical trial, only subjects with a TBS with bleeding of Grade 1 (mild) or Grade 2 (moderate) intensity will be enrolled.

This study includes a Screening Visit to determine subject eligibility, a Baseline Visit, the Surgical Procedure (Day 1), and Post-operative assessments at Days 1, 4, and 30. The total duration of a subject's participation in this study is expected to be no longer than 2 months from the Screening Visit to the Post-operative Day 30 Visit.

Details
Condition Excessive Bleeding During Surgery
Treatment Fibrin Sealant Grifols, EVICEL
Clinical Study IdentifierNCT03461406
SponsorGrifols Therapeutics LLC
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age less than or equal to 17 yrs?
Gender: Male or Female
Do you have any of these conditions: Do you have Excessive Bleeding During Surgery??
Pre-operative
Less than 18 years of age
Requires an elective (non-emergent), open (non-laparoscopic), pelvic, abdominal, or thoracic (non-cardiac) surgical procedure
Subject and/or subject's legal guardian is willing to give permission for the subject to participate in the clinical trial and provide written informed consent for the subject. In addition, assent must be obtained from pediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the clinical trial
Intra-operative
\. Presence of an appropriate (as defined in inclusion criterion 5)
parenchymous or soft tissue TBS identified intra-operatively by the
investigator (the surgeon)
\. TBS has Grade 1 (mild) or Grade 2 (moderate) bleeding intensity according
to the investigator's (the surgeon's) judgment. The intensity of the bleeding
at the TBS will be rated by the investigator using the 5-point validated
bleeding severity scale

Exclusion Criteria

Pre-operative
Admitted for trauma surgery
Unwilling to receive blood products
Known history of severe (eg, anaphylactic) reaction to blood products
Known history of intolerance to any of the components of the investigational product (IP)
Female subjects who are pregnant, breastfeeding or, if of child-bearing potential (ie, adolescent), unwilling to practice a highly effective method of contraception
Previously enrolled in a clinical trial with FS Grifols
Currently participating, or during the study is planned to participate, in any other investigational device or medicinal product study without prior and explicit approval from the sponsor
Intra-operative
\. An appropriate parenchymous or soft tissue TBS (as defined in exclusion
criteria 9 and 10) cannot be identified intra-operatively by the investigator
(the surgeon)
\. TBS has Grade 3 (severe) bleeding according to the investigator's (the
surgeon's) judgment that cannot be controlled with conventional surgical
techniques to Grade 1 or Grade 2 bleeding. The intensity of the bleeding at
the TBS will be rated by the investigator using the 5-point validated bleeding
severity scale
\. TBS is in an actively infected surgical field
\. Occurrence of major intra-operative complications that require
resuscitation or deviation from the planned surgical procedure
\. Application of any topical hemostatic agent on the resection surface of
parenchyma or soft tissue prior to application of the IP
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note